|
|
Phase I/II Study of Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine and ONYCR1, ONYCR2, and ONYCR3 Allogeneic Adenocarcinoma Cell-Based Vaccines in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Colon or Rectum
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
ONYVAX-SGCRO01 NCI-V00-1599, NCT00007826
|
|
|
Objectives - Determine the safety and tolerability of monoclonal antibody 105AD7 anti-idiotypic vaccine and ONYCR1, ONYCR2, and ONYCR3 allogeneic adenocarcinoma cell-based vaccines in patients with locally advanced or metastatic adenocarcinoma of the colon or rectum.
- Determine any immunological response to these treatment regimens in these patients.
- Determine the 6-month and 1-year survival of these patients after receiving these treatment regimens.
- Determine the tumor response to these treatment regimens in these patients.
Entry Criteria Disease Characteristics:
- Histologically or cytologically confirmed locally advanced or metastatic
adenocarcinoma of the colon or rectum
- Not amenable to curative surgery and either
refractory to or inappropriate
for chemotherapy
- Patient must have received adequate or appropriate
prior chemotherapy for
metastatic disease
Prior/Concurrent Therapy:
Biologic therapy: - At least 1 month since prior immunomodulatory drugs
Chemotherapy: - See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- No concurrent chemotherapy
Endocrine therapy: - At least 1 month since prior corticosteroids
- No concurrent corticosteroids
Radiotherapy: - At least 6 weeks since prior radiotherapy
Surgery: - See Disease Characteristics
Other: - At least 4 weeks since other prior anticancer drug
- No other concurrent investigational anticancer agent
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: Hepatic: Renal: Other: - No other prior malignancy within the past 5 years except
adequately treated basal cell carcinoma of the skin or carcinoma in
situ
- No history of immunodeficiency
- No concurrent unstable medical condition that would preclude
study
- No psychological, familial, sociological, or geographical
condition that would preclude study compliance
Expected Enrollment A total of 45 patients (15 per treatment arm) will be accrued for this study. Outline This is an open-label study. Patients are assigned to one of three
treatment arms. - Arm I: Patients receive monoclonal antibody 105AD7 anti-idiotype
vaccine (MOAB 105AD7) plus BCG intradermally (ID) weekly for weeks 1 and 2;
MOAB 105AD7 ID plus alum adjuvant intramuscularly (IM) weekly for weeks 4 and
6; and then MOAB 105AD7 ID alone monthly for up to 12 months.
- Arm II: Patients receive ONYCR1, ONYCR2, and ONYCR3 allogeneic
adenocarcinoma cell-based vaccines plus BCG ID weekly for weeks 1 and 2; these
vaccines ID weekly for weeks 4 and 6, and then monthly for up to 12 months.
- Arm III: Patients receive MOAB 105AD7, ONYCR1, ONYCR2, and ONYCR3
allogeneic adenocarcinoma cell-based vaccines, and BCG ID weekly for weeks 1
and 2; MOAB 105AD7 and ONYCR1, ONYCR2, and ONYCR3 allogeneic adenocarcinoma
cell-based vaccines ID plus alum adjuvant IM weekly for weeks 4 and 6; and
then MOAB 105AD7 and ONYCR1, ONYCR2, and ONYCR3 allogeneic adenocarcinoma
cell-based vaccines monthly for up to 12 months.
Patients are followed every 3 months.
Trial Contact Information
Trial Lead Organizations Onyvax Limited at St. George's Hospital Medical School | | | Fiona Lofts, MD, Protocol chair | | | |
Registry Information | | Official Title | | A Phase I/II Trial of an Allogeneic Cell Based Vaccine and an Anti-Idiotypic Antibody Vaccine Approach for Metastatic Adenocarcinoma of the Colon or Rectum | | Trial Start Date | | 2000-04-25 | | Registered in ClinicalTrials.gov | | NCT00007826 | | Date Submitted to PDQ | | 2000-06-09 | | Information Last Verified | | 2005-02-09 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|